2004 SkyePharma Annual Report 41 Consolidated Profit and Loss Account Before Exceptional Before exceptional items and Year to exceptional Exceptional Year to items and amortisation 31 December items and items and 31 December amortisation note 4 2004 amortisation amortisation 2003 Notes 000 000 000 000 000 000 Turnover 2 62,168 62,168 53,152 53,152 Cost of sales 2 31,154 31,154 29,786 29,786 Gross profit 31,014 31,014 23,366 23,366 Selling, marketing and distribution expenses 1,728 1,728 4,348 4,348 Administration expenses Amortisation 6,314 6,314 6,669 6,669 Other administration expenses 12,226 4,711 16,937 17,987 9,487 27,474 12,226 11,025 23,251 17,987 16,156 34,143 Research and development expenses 27,961 27,961 30,520 30,520 Other operating income 3 1,237 1,237 6,126 6,126 Operating loss 5 9,664 11,025 20,689 23,363 16,156 39,519 Profit on disposal of investment 12 2,021 2,021 Share of loss in associate 10 6 16 Loss on ordinary activities before interest and taxation 9,674 9,010 18,684 23,363 16,156 39,519 Interest receivable 758 758 1,029 1,029 Interest payable 7 5,784 338 6,122 4,493 4,493 Loss on ordinary activities before taxation 2 14,700 9,348 24,048 26,827 16,156 42,983 Taxation 8 248 248 240 240 Retained loss 14,948 9,348 24,296 27,067 16,156 43,223 Basic and diluted loss per Ordinary Share 9 2.4p 1.5p 3.9p 4.4p 2.7p 7.1p There was no material difference between the loss on ordinary activities before taxation and the historical cost loss before taxation in 2004 and 2003.
All results represent continuing activities.
See Notes to the Financial Statements.
